The new law will require drug producers to pay back 12% of their turnover on state-subsidised drugs into the budget, pay a Ft 5 million annual fee per sales agent and pay for more than half of any subsidy spending overshoot in the budget. Egis CEO Péterné Gál told that the new law posed a threat to innovation within the domestic pharmaceutical industry. Gál told the paper that, as a first step, Egis had reviewed its product portfolio and decided to take out products that would no longer be economical due to a rise in costs. This may affect about 10% of Egis’s portfolio, which contains 1,650 products. (portfolio.hu)